Literature DB >> 33643226

Predominance of Non-carbapenemase Producing Carbapenem-Resistant Enterobacterales in South Texas.

Cody A Black1,2,3, Wonhee So4, Steven S Dallas2,3, Gerard Gawrys1,5, Raymond Benavides1,2, Samantha Aguilar1,2,3, Chang-Jui Chen1,2, James F Shurko1,2, Grace C Lee1,2.   

Abstract

BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) pose a significant global public health threat. Resistance among CRE is particularly complex, owing to numerous possible resistance mechanisms and broad definitions. We aimed to characterize the clinical and molecular profiles of CRE in the South Texas region.
MATERIALS AND METHODS: We compared the clinical, genotypic, and phenotypic profiles of carbapenemase producing Enterobacterales (CPE) with those of non-carbapenemase producers (NCPE) isolated from South Texas, United States between 2011 and 2019. Molecular characteristics and resistance mechanisms were analyzed using whole-genome sequences.
RESULTS: The majority (59%) of the CRE isolates were NCPE while 41% of isolates harbored carbapenemases, predmonantly bla KPC-type. The most common CPE was Klebsiella pneumoniae while majority of Enterobacter cloacae and Escherichia coli were NCPE Among K. pneumoniae, the clonal group 307 has emerged as a predmoninant group and was associated with as many CRE infections as the previous common clonal group 258. Patients with NCPE compared to CPE infections were associated with higher antimicrobial exposure prior to culture collection (days of therapy, 795 vs. 242; p < 0.001) and emergency department visits within past 90 days (22% vs. 4%; p = 0.011). The all cause 30-day mortality was 21%.
CONCLUSIONS: This study highlights the diversity of resistance mechanisms underlying CRE in South Texas, with 59% not harboring a carbapenemase. Individuals with NCPE infections were more likely to have had prior antimicrobial therapy and emergency department visits compared to those with CPE. Identification and distinction of these mechanisms by rapid identification of species and carbapenemase would allow for optimal treatment and infection control efforts.
Copyright © 2021 Black, So, Dallas, Gawrys, Benavides, Aguilar, Chen, Shurko and Lee.

Entities:  

Keywords:  Enterobacterales; carbapenem; epidemiology; outcomes; resistance

Year:  2021        PMID: 33643226      PMCID: PMC7902696          DOI: 10.3389/fmicb.2020.623574

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


  16 in total

1.  Acquisition of carbapenem resistance in multiresistant Klebsiella pneumoniae strains harbouring blaCTX-M-15, qnrS1 and aac(6')-Ib-cr genes.

Authors:  Elena Ruiz; Alain A Ocampo-Sosa; Antonio Rezusta; María José Revillo; Elena Román; Carmen Torres; Luis Martínez-Martínez
Journal:  J Med Microbiol       Date:  2012-01-26       Impact factor: 2.472

Review 2.  The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria.

Authors:  Jean-Marie Pagès; Chloë E James; Mathias Winterhalter
Journal:  Nat Rev Microbiol       Date:  2008-11-10       Impact factor: 60.633

3.  Genomic characterisation of Klebsiella michiganensis co-producing OXA-181 and NDM-1 carbapenemases isolated from a cancer patient in uMgungundlovu District, KwaZulu-Natal Province, South Africa.

Authors:  R C Founou; L L Founou; M Allam; A Ismail; S Y Essack
Journal:  S Afr Med J       Date:  2018-12-13

4.  Emergence of IncFIA Plasmid-Carrying blaNDM-1 Among Klebsiella pneumoniae and Enterobacter cloacae Isolates in a Tertiary Referral Hospital in Mexico.

Authors:  María Dolores Alcántar-Curiel; José Luis Fernández-Vázquez; José Eduardo Toledano-Tableros; Catalina Gayosso-Vázquez; Ma Dolores Jarillo-Quijada; María Del Rocío López-Álvarez; Silvia Giono-Cerezo; José Ignacio Santos-Preciado
Journal:  Microb Drug Resist       Date:  2019-03-05       Impact factor: 3.431

5.  Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013.

Authors:  Alice Y Guh; Sandra N Bulens; Yi Mu; Jesse T Jacob; Jessica Reno; Janine Scott; Lucy E Wilson; Elisabeth Vaeth; Ruth Lynfield; Kristin M Shaw; Paula M Snippes Vagnone; Wendy M Bamberg; Sarah J Janelle; Ghinwa Dumyati; Cathleen Concannon; Zintars Beldavs; Margaret Cunningham; P Maureen Cassidy; Erin C Phipps; Nicole Kenslow; Tatiana Travis; David Lonsway; J Kamile Rasheed; Brandi M Limbago; Alexander J Kallen
Journal:  JAMA       Date:  2015-10-13       Impact factor: 56.272

6.  Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia.

Authors:  Abraham Borer; Lisa Saidel-Odes; Klaris Riesenberg; Seada Eskira; Nejama Peled; Ronit Nativ; Francisc Schlaeffer; Michael Sherf
Journal:  Infect Control Hosp Epidemiol       Date:  2009-10       Impact factor: 3.254

7.  Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey.

Authors:  Ufuk Over Hasdemir; Jacqueline Chevalier; Patrice Nordmann; Jean-Marie Pagès
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

8.  Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Authors:  David van Duin; Judith J Lok; Michelle Earley; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Vance G Fowler; David L Paterson; Robert A Bonomo; Scott Evans
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

9.  Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae.

Authors:  Nora Chea; Sandra N Bulens; Thiphasone Kongphet-Tran; Ruth Lynfield; Kristin M Shaw; Paula Snippes Vagnone; Marion A Kainer; Daniel B Muleta; Lucy Wilson; Elisabeth Vaeth; Ghinwa Dumyati; Cathleen Concannon; Erin C Phipps; Karissa Culbreath; Sarah J Janelle; Wendy M Bamberg; Alice Y Guh; Brandi Limbago; Alexander J Kallen
Journal:  Emerg Infect Dis       Date:  2015-09       Impact factor: 6.883

10.  RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

Authors:  Johann Motsch; Cláudia Murta de Oliveira; Viktor Stus; Iftihar Köksal; Olexiy Lyulko; Helen W Boucher; Keith S Kaye; Thomas M File; Michelle L Brown; Ireen Khan; Jiejun Du; Hee-Koung Joeng; Robert W Tipping; Angela Aggrey; Katherine Young; Nicholas A Kartsonis; Joan R Butterton; Amanda Paschke
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

View more
  3 in total

1.  Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX.

Authors:  William C Shropshire; An Q Dinh; Michelle Earley; Lauren Komarow; Diana Panesso; Kirsten Rydell; Sara I Gómez-Villegas; Hongyu Miao; Carol Hill; Liang Chen; Robin Patel; Bettina C Fries; Lilian Abbo; Eric Cober; Sara Revolinski; Courtney L Luterbach; Henry Chambers; Vance G Fowler; Robert A Bonomo; Samuel A Shelburne; Barry N Kreiswirth; David van Duin; Blake M Hanson; Cesar A Arias
Journal:  mBio       Date:  2022-03-31       Impact factor: 7.786

2.  Clinical epidemiology of carbapenem-resistant Enterobacterales in the Greater Houston region of Texas: a 6-year trend and surveillance analysis.

Authors:  Bekana K Tadese; Charles Darkoh; Stacia M DeSantis; Osaro Mgbere; Kayo Fujimoto
Journal:  J Glob Antimicrob Resist       Date:  2022-06-25       Impact factor: 4.349

Review 3.  Immune-microbiome interplay and its implications in neurodegenerative disorders.

Authors:  Ankit Uniyal; Vineeta Tiwari; Mousmi Rani; Vinod Tiwari
Journal:  Metab Brain Dis       Date:  2021-08-06       Impact factor: 3.584

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.